Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Provenge Data Not Supportive Of Off-Label Uses, MEDCAC Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

The existing clinical data on Dendreon's prostate cancer vaccine Provenge cannot be "generalizable" to off label uses, most members of the Medicare Evidence Development and Coverage Advisory Committee agreed at a Nov. 17 meeting.

You may also be interested in...



FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO

The two major trade associations representing drug and biological manufacturers are telling FDA and CMS that their proposed parallel review process is neither appropriate nor necessary for biopharma products.

FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO

The two major trade associations representing drug and biological manufacturers are telling FDA and CMS that their proposed parallel review process is neither appropriate nor necessary for biopharma products.

Provenge Coverage With Data Collection Suggested By MEDCAC Members

The Centers for Medicare and Medicaid Services got a number of suggestions about linking Medicare coverage with data collection for Dendreon’s therapeutic prostate cancer vaccine Provenge at the Medicare Evidence Development and Coverage Advisory Committee’s Nov. 17 meeting.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel